Vol.:(0123456789) 1 3
Cellular and Molecular Life Sciences (2018) 75:3313â€“3327 
https://doi.org/10.1007/s00018-018-2860-6
REVIEW
Molecular mechanisms ofÂ hepatic lipid accumulation inÂ nonâ€‘alcoholic 
fatty liver disease
DavidÂ HÃ¸jlandÂ Ipsen1Â Â· JensÂ Lykkesfeldt1Â Â· PernilleÂ Tvedenâ€‘Nyborg1
Received: 5 April 2018 / Revised: 18 June 2018 / Accepted: 20 June 2018 / Published online: 23 June 2018 
Â© The Author(s) 2018
Abstract
Non-alcoholic fatty liver disease (NAFLD) is currently the worldâ€™s most common liver disease, estimated to afect up to 
one-fourth of the population. Hallmarked by hepatic steatosis, NAFLD is associated with a multitude of detrimental efects 
and increased mortality. This narrative review investigates the molecular mechanisms of hepatic steatosis in NAFLD, focusing on the four major pathways contributing to lipid homeostasis in the liver. Hepatic steatosis is a consequence of lipid 
acquisition exceeding lipid disposal, i.e., the uptake of fatty acids and de novo lipogenesis surpassing fatty acid oxidation 
and export. In NAFLD, hepatic uptake and de novo lipogenesis are increased, while a compensatory enhancement of fatty 
acid oxidation is insufcient in normalizing lipid levels and may even promote cellular damage and disease progression by 
inducing oxidative stress, especially with compromised mitochondrial function and increased oxidation in peroxisomes and 
cytochromes. While lipid export initially increases, it plateaus and may even decrease with disease progression, sustaining 
the accumulation of lipids. Fueled by lipo-apoptosis, hepatic steatosis leads to systemic metabolic disarray that adversely 
afects multiple organs, placing abnormal lipid metabolism associated with NAFLD in close relation to many of the current 
life-style-related diseases.
Keywords Lipid metabolismÂ Â· Animal modelsÂ Â· Pharmacotherapy
Introduction
Afecting 25% of the adult population, non-alcoholic fatty 
liver disease (NAFLD) is currently the most common liver 
disease in the world [1]. Regional prevalence rates are currently highest in the Middle East (32%) and South America 
(30%) and lowest in Africa (13%), but prevalence rates are 
even higher in specifc subpopulations such as severely 
obese (90%) and patients with type 2 diabetes (76%) [1]. 
Furthermore, NAFLD in lean individuals is far from uncommon with prevalence rates around 16% [2, 3]. NAFLD is 
associated with increased mortality, particularly due to cardiovascular disease, hepatocellular carcinoma, and liverrelated events [4]. The escalating prevalence, particularly 
during the last decades, has made NAFLD the second most 
common cause of liver transplantation in the United States 
[5]. The hallmark of NAFLD is hepatic steatosis, but the 
disease also encompasses non-alcoholic steatohepatitis 
(NASH) characterized by hepatic infammation, hepatocyte 
damage, and fbrosis, highlighting the potentially progressive nature of the disease. The stage of hepatic fbrosis 
predicts both overall and liver-related mortality and is the 
strongest predictor of long-term clinical outcomes, with 
advanced fbrosis (stages 3 and 4) conveying the highest 
risk of mortality [6]. However, progression to fbrosis also 
occurs in patients with steatosis alone [7], although rates 
of progression and overall mortality rates are increased in 
NASH [1, 8]. In addition, metabolic dysfunctions, such as 
insulin resistance, dyslipidemia, and cardiovascular disease 
are all associated with hepatic steatosis, and seem to be more 
related to hepatic fat accumulation and NAFLD than obesity 
status per se [2, 9, 10].
The liver constitutes an essential organ in lipid metabolism. As a central regulator of lipid homeostasis, the liver 
is responsible for orchestrating the synthesis of new fatty 
acids, their export and subsequent redistribution to other 
tissues, as well as their utilization as energy substrates [11] 
(Fig.Â 1). These processes are closely regulated by complex 
Cellular and Molecular Life Sciences
* Pernille Tveden-Nyborg 
ptn@sund.ku.dk
1 Department ofÂ Veterinary andÂ Animal Sciences, Faculty 
ofÂ Health andÂ Medical Sciences, University ofÂ Copenhagen, 
Ridebanevej 9, 1870Â FrederiksbergÂ C, Denmark

3314 D.Â H.Â Ipsen et al.
1 3
interactions between hormones, nuclear receptors, and transcription factors, keeping hepatic lipid homeostasis under 
tight control [12]. The disruption of one or more of these 
pathways may precipitate the retention of fat within the 
liver and the subsequent development of NAFLD. Hepatic 
fat accumulation results from an imbalance between lipid 
acquisition and lipid disposal, which are regulated through 
four major pathways: uptake of circulating lipids, de novo 
lipogenesis (DNL), fatty acid oxidation (FAO), and export 
of lipids in very low-density lipoproteins (VLDL) (Fig.Â 2). 
However, the molecular mechanisms underlying the pathological aggregation of fat within the liver are not fully elucidated. This review explores current insights to these four 
pathways and the molecular mechanisms regulating hepatic 
lipid homeostasis in NAFLD, discussing processes that 
may be instrumental in the development and progression of 
hepatic steatosis.
Hepatic lipid uptake
The uptake of circulating fatty acids by the liver is largely 
dependent on fatty acid transporters, while passive difusion 
contributes less [13]. The transport is predominately mediated by fatty acid transport proteins (FATP), cluster of diferentiation 36 (CD36), and caveolins located in the hepatocyte 
plasma membrane [14] (Fig.Â 3). Of the six mammalian FATP 
isoforms, FATP2 and FATP5 are found primarily in the liver 
[14]. Knockdown of FATP2 in mice decreases uptake of 
fatty acids and ameliorates hepatic steatosis induced by 
a high fat diet [15]. Likewise, knockout or knockdown of 
FATP5 in mice reduces hepatocyte fatty acid uptake, hepatic 
triglyceride content, and reverses steatosis [16, 17] indicating a role of FATP-mediated lipid uptake as a facilitator 
of hepatic steatosis. FATP2 and 5 gene expression was 
increased in adolescents with NASH (n=27) compared to 
normal controls (n=6) [18]. In contrast, a small study found 
no diference in hepatic FATP5 gene expression between 
individuals with (n=16) and without (n=8) hepatic steatosis [19]. FATP5 promotor polymorphism (rs56225452), representing a putative gain-of-function mutation in the FATP5 
promotor, correlated with BMI-dependent hepatic steatosis 
in males with biopsy proven NAFLD (n=103) [20], suggesting that genetic variation may underlie part of the contribution of FATP5 in NAFLD. However, additional studies are 
required to extend our present understanding of the role of 
FATP in clinical NAFLD.
The fatty acid translocase protein, CD36, facilitates the 
transport of long-chain fatty acids and is regulated by peroxisome proliferator-activated receptor (PPAR) Î³, pregnane X 
receptor, and liver X receptor [21]. Mice fed a high fat diet 
develop hepatic steatosis alongside increased mRNA and 
protein expression of CD36 [22, 23]. Adenovirus-mediated 
overexpression of CD36 enhances hepatic fatty acid uptake 
and fat accumulation [22], while liver-specifc knockout of 
CD36 decreases hepatic lipid levels in both genetic and dietinduced steatosis [23]. This suggests a causal role of CD36 
in steatosis supported by abnormally increased CD36 levels 
in NAFLD patients: a small study reported increased CD36 
mRNA levels in obese subjects with high amounts of intracellular fat (66.0Â±6.8%, n=5), compared to subjects with 
low liver fat content (6.4Â±2.7%, n=5) [24]. In adolescents 
and adults of both genders, diagnosed with NASH or hepatic 
steatosis, CD36 gene and protein expression were increased 
compared to healthy controls; however, CD36 levels did not 
difer between patients with steatosis and NASH [18, 25]. 
In contrast, hepatic levels of CD36 were found to be similar 
in morbidly obese women with hepatic steatosis compared 
to morbidly obese controls with normal livers [26]. However, the conficting fndings of expression patterns may not 
adequately illustrate a functional consequence of the role 
of CD36. Immunohistochemistry of liver sections showed 
CD36 as located in the hepatocyte plasma membrane in 
patients with steatosis and NASH, compared to a weak 
CD36 expression confned to the cytoplasm of hepatocytes 
in normal livers, suggesting that the translocation of CD36 
protein from cytoplasm to membrane may be a triggering 
event in NAFLD progression [25].
The caveolins comprise a family of three membrane 
proteins contributing to lipid trafcking and formation of 
lipid droplets [14]. Caveolin 1 was increased in the liver 
of mice with NAFLD, and located mainly in the centrilobular zone 3, where the steatosis was most severe [27]. 
Lipids
Uptake of circulang fay acids
De novo
lipogenesis
Oxidaon
Export
Fay acid transporters
VLDL
Mitochondria
Cytochromes
Peroxisomes
Fig. 1 Hepatic lipid acquisition and disposal. Intrahepatic lipid levels 
are governed by the balance between lipid acquisition and disposal 
constituting the four major pathways of hepatic lipid homeostasis. The liver acquires lipids through the uptake of circulating fatty 
acids and via de novo lipogenesis. Conversely, lipids may be disposed of through oxidation (in the mitochondria, peroxisomes and 
cytochromes) and through export as very low density lipoprotein 
(VLDL) particles. Consequently, lipid accumulation is the result of 
lipid acquisition pathways exceeding disposal pathways

Molecular mechanisms ofÂ hepatic lipid accumulation inÂ non-alcoholic fatty liver disease 3315
1 3
Similarly, zone 3 predominant hepatic steatosis is reported 
in adult NAFLD patients [28]. Whole-body caveolin 1 
knockout (cav1âˆ’/âˆ’) reduced hepatic steatosis in high fat 
fed mice in response to 24Â h of fasting, whereas liverspecifc caveolin 1 knockout did not afect hepatic fat content [29]. Reduced hepatic steatosis in fasted cav1âˆ’/âˆ’ mice 
was suggested to be secondary to compromised metabolic 
function in the adipose tissue, resulting in reduced hepatic 
DNL (and possibly increased FAO) [29]. In contrast, 
decreased caveolin 1 expression has been reported in the 
livers of high fat fed mice with NAFLD [30]. Furthermore, 
caveolin 1 knockout augmented steatosis both inÂ vitro and 
inÂ vivo by enhancing the expression of genes involved in 
DNL [30], contradicting earlier studies, and suggesting 
a protective efect of caveolin 1 in NAFLD [30]. Diferential observations suggest that the role of caveolin 1 in 
hepatic lipid accumulation may difer depending on how 
the steatosis is induced, e.g., via high fat diet or fasting. 
However, long-term fasting is typically not the primary 
cause of NAFLD, and results from such models should 
consequently be translated with caution.
Following uptake, hydrophobic fatty acids do not difuse 
freely in the cytosol and must instead be shuttled between 
diferent organelles by specifc fatty acid binding proteins 
(FABP) of which FABP1, also known as liver FABP, is the 
predominant isoform in the liver [13]. FABP1 facilitates 
the transportation, storage, and utilization of fatty acids 
and their acyl-CoA derivatives and may exert a protective 
efect against lipotoxicity by binding otherwise cytotoxic 
free fatty acids and facilitating their oxidation or incorporation into triglycerides [31]. FABP1 also afects the expression of PPARÎ± and PPARÎ³ by mediating the transport of 
PPAR ligands to the nucleus of hepatocytes, and intracellular FABP1 concentrations are correlated with PPARÎ± 
and PPARÎ³ activities [32]. Hepatic triglycerides and lipid 
disposal pathways (fatty acid export and oxidation) are 
decreased following FABP1 ablation in fasted mice, suggesting that reduced levels of liver triglycerides are linked to 
Triglyceride
Fay acid
PPARÎ³
FABP1
Mitochondrial
Î²-oxidaon
CPT
Peroxisomal
Î²-oxidaon
Cytochrome
Ï‰-oxidaon
Acetyl-CoA
Fay acid
VLDL
SREBP1c
ChREBP PPARÎ±
Lipid acquision Lipid disposal
ROS
1
2
3
4 De novo lipogenesis
Fig. 2 Overview of hepatic lipid metabolism. (1) Uptake of circulating lipids are facilitated by specifc fatty acid transporters located in 
the hepatocyte plasma membrane and is regulated by PPARÎ³. FABP1 
facilitates the transport of hydrophobic fatty acids to the diferent cellular compartments within the cytoplasm. (2) De novo lipogenesis 
converts acetyl-CoA (originating from excess carbohydrates) to new 
fatty acids, which subsequently can be esterifed and stored as triglycerides. Regulation of de novo lipogenesis is complex, but broadly 
controlled by two key transcription factors: SREBP1c and ChREBP. 
(3) Fatty acid oxidation is controlled by PPARÎ± and reduces intrahepatic fat levels by utilizing lipids as an energy source. While the 
process primarily occurs in the mitochondria, lipid overload and/or 
compromised mitochondrial function forces a higher degree of fatty 
acid oxidation to take place in the peroxisomes and cytochromes, 
thereby, generating ROS. (4) The liver can export lipids by packaging 
them into water-soluble VLDL-particles, which may then be utilized 
or stored in other tissues. ChREBP carbohydrate regulatory element 
binding protein, CPT carnitine palmitoyltransferase, FABP fatty acid 
binding protein, PPAR peroxisome proliferator-activated receptor, 
ROS reactive oxygen species, SREBP1c sterol regulatory element 
binding protein 1c, VLDL very low density lipoprotein

3316 D.Â H.Â Ipsen et al.
1 3
a reduced hepatic lipid uptake, at least in the fasted state in 
which lipid fux to the liver is increased [33, 34]. In patients 
with NAFLD, hepatic FABP1, FABP4, and FABP5 mRNA 
levels were increased compared to non-NAFLD controls 
and FABP4 and 5 correlated with the percentage of liver 
fat [19, 35]. Thus, enhanced intracellular trafcking of fatty 
acids in the lipid laden liver of NAFLD patients may be 
shunting harmful fatty acids to storage, thereby promoting 
steatosis. FABP levels may vary according to disease severity as FABP1 protein levels were overexpressed in obese 
patients with steatosis (n=10) compared to obese controls 
(n=10), but decreased in NASH patients with mild fbrosis (n=10) and declining further in NASH with advanced 
fbrosis (n=10) [36]. Thus, increased FABP1 in the earlier 
stages of NAFLD may enhance lipid fux as a compensatory 
mechanism to limit lipotoxicity. As the disease progresses, 
desaturaon
Cytoplasmic
CD36
CD36
Triglyceride
Fay acid
FABP1
Acetyl-CoA
Malonyl-CoA
ACC
FASN
Palmitate
Elongaon &
Oleic acid
Esterificaon
SCD1
ELOVL6
Diglyceride
acyltransferase
MTTP ApoB100
Fay acid
VLDL
SREBP1c
ChREBP
Caveolins
Diacylglyceride Protein
kinase CÏµ
Insulin
resistance
PPARÎ±
Liver damage
Membrane
translocaon
FATP2
FATP5 
Endoplasmic 
reculum 
stress
Extracellular
Intracellular
Mitochondrial
Î²-oxidaon
Peroxisomal
Î²-oxidaon
Cytochrome
Ï‰-oxidaon
CYP4A11
CYP2E1
An-oxidants
Compromised
respiratory chain
ROS
Ultrastructural
changes
Fig. 3 Efects on hepatic lipid metabolism in NAFLD. While the role 
of hepatic caveolins is still unclear, CD36, FATP2 and -5 mediates 
increased uptake of circulating lipids in NAFLD. Initially, FABP1 
is increased, but levels may decline with disease progression, potentially limiting the mobility of fatty acids and sustaining steatosis. 
Enhanced SREBP1c-mediated de novo lipogenesis is a key feature of 
NAFLD contributing signifcantly to the accumulation of lipids. At 
the same time, ChREBP which could be hepatoprotective, appears to 
be downregulated in NAFLD. Although data relating to the regulation of fatty acid oxidation are conficting, mitochondrial dysfunction 
is an important feature of NAFLD resulting in increased generation 
of ROS and utilization of cytochrome- and peroxisome-mediated 
oxidation. This further promotes oxidative stress, in turn inducing 
damage to the mitochondrial membranes, compromising cellular respiration and metabolism, and impairing liver function by direct and 
indirect cellular damage. Lastly, lipid export increases with hepatic 
triglyceride levels. However, in the setting of NASH, levels of MTTP 
and apoB100 may be decreased, hereby, limiting VLDL export and 
instead facilitating lipid accumulation. The net result is an escalating 
vicious circle, driven by chronic dyslipidemia and hepatic lipid overload, leading to detrimental consequences for liver metabolism and 
function and ultimately promoting irreversible liver damage. Green 
arrow: increased expression. Red arrow: decreased expression. Purple 
arrow: expression diferent between steatosis and NASH. ACC acetylCoA carboxylase, ApoB100 apolipoprotein B100, CD36 cluster of 
diferentiation 36, ChREBP carbohydrate regulatory element binding 
protein, ELOVL elongation of very long chain fatty acid, FABP fatty 
acid binding protein, FASN fatty acid synthase, FATP fatty acid transport protein, MTTP microsomal triglyceride transfer protein, PPAR
peroxisome proliferator-activated receptor, ROS reactive oxygen species, SCD1 stearoyl-CoA desaturase 1, SREBP1c sterol regulatory 
element binding protein 1c, VLDL very low density lipoprotein

Molecular mechanisms ofÂ hepatic lipid accumulation inÂ non-alcoholic fatty liver disease 3317
1 3
diminishing levels of FABP1 potentially leads to increased 
levels of lipids, with ensuing lipotoxicity promoting disease 
progression by damaging essential organelles and cells in 
the liver (Fig.Â 3).
De novo lipogenesis
In short, DNL enables the liver to synthesize new fatty 
acids from acetyl-CoA. Initially, acetyl-CoA is converted 
to malonyl-CoA by acetyl-CoA carboxylase (ACC) and 
malonyl-CoA is then converted to palmitate by fatty acid 
synthase (FASN). New fatty acid may then undergo a range 
of desaturation, elongation, and esterifcation steps before 
ultimately being stored as triglycerides or exported as VLDL 
particles (Fig.Â 3). Thus, increased DNL can cause hepatic 
steatosis and/or hypertriglyceridemia, but may also induce 
steatohepatitis, as saturated fatty acids, such as palmitate, 
can cause infammation and apoptosis [37]. Studies using 
stable isotope tracers suggest that an important characteristic 
of NAFLD patients is abnormally elevated DNL regardless 
of fasting. Accordingly, a small study reported increased 
DNL in NAFLD patients (n=5) compared to controls (n=6) 
[38]. These fndings are supported by enhanced DNL in 
overweight/obese subjects with high liver fat (18.3Â±3.6%, 
n=13) compared to those with lower liver fat (3.1Â±2.7%, 
n=11) while being matched for adiposity and circulating 
lipids [39]. In addition, DNL was independently associated 
with intrahepatic triglyceride levels [39], and inadequate 
suppression of DNL during fasting could be a key feature 
in NAFLD patients [38, 39]. The importance of DNL in 
NAFLD is further supported by studies, showing that in 
obese patients with NAFLD, approximately 26% of hepatic 
triglycerides were derived from DNL and that these patients 
were unable to regulate DNL when transitioning from fasting to fed state [40]. While limited, the available clinical data 
collectively indicate that failure to regulate DNL is a central 
feature of liver lipid accumulation in NAFLD patients.
The transcriptional regulation of DNL is mainly orchestrated by two key transcription factors: sterol regulatory 
element-binding protein 1c (SREBP1c), which is activated 
by insulin and liver X receptor Î±, and carbohydrate regulatory element-binding protein (ChREBP), which is activated 
by carbohydrates [41â€“43] (Fig.Â 2). SREBP1c expression is 
enhanced in patients with NAFLD, and in agreement with 
its lipogenic role, hepatic triglyceride levels are higher in 
transgenic mice overexpressing SREBP1c [44, 45], while 
SREBP1c knockout mice display decreased expression of 
lipogenic enzymes [46]. SREBP1c ablation also promotes a 
compensatory upregulation of SREBP2, leading to increased 
hepatic cholesterol synthesis and cholesterol accumulation, 
linking DNL to cholesterol metabolism [46]. While the phenotypic insulin resistance in NAFLD would be expected to 
counteract insulin-mediated SREBP1c activation, a state 
of selective insulin resistance ensures that insulin retains 
its ability to promote DNL through SREBP1c while being 
unable to suppress gluconeogenesis [41]. This helps may 
explain the observed elevated rates of hepatic DNL under 
insulin resistant conditions. In addition, SREBP1c indirectly 
contributes to the development of hepatic insulin resistance, 
since enhanced lipogenesis and subsequent accumulation of 
harmful lipid species, such as diacylglycerides, may interfere with insulin signaling (as discussed below). ChREBP 
mediates carbohydrate, but not fat-induced DNL as high 
fat diets do not activate ChREBP and may even decrease 
ChREBP activity [43, 47]. In mice, knockout of ChREBP 
has been shown to reduce hepatic fatty acid synthesis by 
65% compared to wild-type controls, but also to promote 
insulin resistance, delayed glucose clearance, and severe 
intolerance to simple carbohydrates, such as sucrose and 
fructose (resulting in death in the majority of animals) due 
to an inability to shunt fructose into glycolytic pathways 
[48]. This emphasizes the essential role of ChREBP in both 
lipid and glucose metabolisms and suggests that ChREBP 
is required for a normal lipogenic response following the 
ingestion of carbohydrates [48]. In ob/ob mice, silencing 
ChREBP reduces hepatic triglyceride content specifcally 
through inhibition of glucose-induced lipogenesis [49]. 
Likewise, ChREBP knockout protected against fructoseinduced steatosis in mice, but substantially increased histological liver damage as a result of enhanced cholesterol 
synthesis and subsequent cytotoxicity [50]. By limiting 
levels of cytotoxic-free cholesterol and the subsequent liver 
injury, ChREBP may confer a hepatoprotective efect [50]. 
Increased ChREBP levels in NAFLD could then constitute a 
potential defense mechanism shielding the liver from further 
injury and progression towards NASH. Supporting this concept, lipogenesis has been reported to be dissociated from 
NASH progression, i.e., elevated DNL may induce steatosis, 
but may be protective in relation to disease progression [51]. 
High ChREBP expression was found in biopsies from NASH 
patients, but levels declined in patients with severe insulin 
resistance, indicating that ChREBP may segregate hepatic 
steatosis from insulin resistance [52]. In high fat fed mice, 
adenovirus-mediated ChREBP overexpression resulted 
in hepatic steatosis and increased DNL. However, insulin 
sensitivity and glucose tolerance were maintained, likely 
owing to an increased conversion of saturated fatty acids 
(known to cause insulin resistance) to monounsaturated 
fatty acids mediated by stearoyl-CoA desaturase-1 (SCD1) 
[52]. ChREBP was down-regulated in patients with NAFLD 
(n=22) compared to healthy controls (n=10), and instead, 
SREBP1c was reported to be one of the predominant regulators of DNL in NAFLD, upregulating genes coding for 
ACC1 and FAS [53].

3318 D.Â H.Â Ipsen et al.
1 3
In response to elevated SREBP1c, the expression of 
downstream targets ACC and FASN was increased in 
both patients and animal models with NAFLD [18, 44, 45, 
53â€“57]. Liver-specifc knockout of ACC1 decreased hepatic 
lipid accumulation in mice and DNL in hepatocytes [58]. 
However, knockout mice were not protected from hepatic 
steatosis induced by a high fat diet, potentially due to 
decreased fatty acid oxidation caused by a compensatory 
increase of ACC2, which in turn inhibited mitochondrial 
Î²-oxidation [58]. Accordingly, inhibition of both ACC1 and 
ACC2 was required to improve hepatic steatosis in mice 
[59], implying that both isoforms are important in NAFLD. 
Paradoxically, liver-specific FASN knockout promoted 
hepatic steatosis in mice on a zero-fat diet [60], in which 
steatosis developed alongside defective PPARÎ± signaling 
and with a phenotype that could be corrected by dietary 
fat or a PPARÎ± agonist [60]. The study identifed â€˜newâ€™ 
lipids, formed either through DNL or originating from the 
diet, as potential PPARÎ± ligands contributing to the regulation of hepatic lipid homeostasis [60]. As mentioned, 
conversion of saturated fatty acids to mono-unsaturated 
fatty acids by SCD1 may be protective in NAFLD [52]. In 
agreement, incubation of hepatocytes with saturated fatty 
acids decreased cell viability, while incubation with monounsaturated fatty acids enhanced lipid accumulation without 
afecting cellular viability [61]. Despite preventing steatosis, SCD1 knockout exacerbated hepatic fbrosis and cellular 
apoptosis in mice with NASH induced by a methionine and 
choline defcient diet [61]. The end-result of SCD1 inhibition may, therefore, be an aggravation of NASH due to 
intracellular accumulation of cytotoxic saturated fatty acids 
[51, 62], placing the partitioning of saturated fatty acids to 
mono-unsaturated fatty acids as a protective factor in delaying NAFLD progression. In view of the considerable crosstalk between the molecular pathways in hepatic lipid homeostasis, inhibition of DNL is not a trivial task, even though it 
may constitute an attractive therapeutic target.
Ectopic lipid deposition directly promotes insulin 
resistance, which is a common feature of patients with 
NAFLD-associated diseases [63, 64]. Insulin sensitivity in 
liver, muscles, and adipose tissue was reduced in subjects 
with high amounts of hepatic lipids (25.3Â±3.5%, n=10) 
compared to individuals with normal levels of hepatic 
lipids (3.6 Â± 0.5%, n = 10) matched for visceral adipose 
tissue volume [65]. Furthermore, hepatic insulin sensitivity was only compromised in obese individuals (n= 20) 
when NAFLD was present [66]. As not all patients with 
fatty livers develop NASH, some individuals must possess protective mechanisms to shield them from lipotoxicity, e.g., lipid desaturation and inhibition of lipid-induced 
infammation [67]. In the promotion of insulin resistance, 
diacylglycerides have emerged as potential mediators. Diacylglycerides are precursors of triglycerides, and hepatic 
accumulation of diacylglycerides has been associated 
with hepatic insulin resistance through the induction of 
protein kinase CÎµ [68]. Transgenic mice overexpressing 
diglyceride acyltransferase 2â€”catalyzing the conversion 
of diglycerides to triglyceridesâ€”increased hepatic triglyceride content fvefold without afecting insulin sensitivity 
[69]. Likewise, antisense oligonucleotides against protein 
kinase CÎµ protected rats from diet-induced hepatic insulin resistance [70]. Conversely, inhibition of diglyceride 
acyltransferase 2 with antisense oligonucleotides in db/db
mice fed a methionine and choline-defcient diet-reduced 
hepatic steatosis, but augmented hepatic infammation, 
fbrosis, and apoptosis [71]. Based on magnetic resonance 
spectroscopy, livers of obese subjects were classifed with 
no steatosis (<5.56%, n=52), mild steatosis (5.56â€“15%, 
n=41), or severe steatosis (>15%, n=40), revealing that 
the presence of NAFLD, but not the amount of hepatic 
triglycerides, was associated with hepatic insulin resistance [72]. When investigating liver biopsies from a subset 
of the subjects (n=27), only cytoplasmic diacylglyceride 
levels, and not total or membrane-associated diacylglycerides, predicted hepatic insulin resistance [72]. Enhanced 
membrane translocation of protein kinase CÏµ (i.e., activation) provides a potential mechanism for diacylglycerideinduced insulin resistance, suggesting hepatic diacylglyceride to be a relevant predictor of insulin resistance 
in NAFLD [72, 73]. In patients with steatosis (n = 9) or 
NASH (n=9), hepatic diacylglyceride levels were equally 
increased compared to controls (n =9) [74]. In addition, 
diglyceride acyltransferases 1 and 2 were not diferentially 
expressed between patients with steatosis (n = 51) and 
NASH (n=53) [75]. It appears that once steatosis is established, further NAFLD/NASH progression does not promote additional alterations in diacylglyceride-linked lipid 
metabolism, rendering diacylglycerides to exert an adverse 
efect already during the early stages of NAFLD development. The ongoing accumulation of hepatic triglyceride 
may represent a compensatory measure implemented to 
convey some degree of protection against more harmful 
lipid species. Though possibly an appealing thought, steatosis should not be interpreted as being benefcial, since 
chronic hepatic steatosis is associated with several serious conditions, including dyslipidemia and hypertension, 
imposing considerable negative efects on the quality of 
life as well as increasing mortality in aficted patients 
[76].
Collectively, lipid accumulation in NAFLD is supported 
by enhanced lipogenesis, denoting DNL as a potential therapeutic target. However, blocking specifc enzymes related to 
DNL may, in some cases, exacerbate NASH and the accompanying metabolic deterioration by promoting accumulation 
of cytotoxic lipid species, indicating the importance of the 
composition of the fatty acid pool in the liver (Fig.Â 3).

Molecular mechanisms ofÂ hepatic lipid accumulation inÂ non-alcoholic fatty liver disease 3319
1 3
Oxidation ofÂ fatty acids
Oxidation of fatty acids is controlled by PPARÎ± and occurs 
mainly in the mitochondria, providing a source of energy 
to generate ATP especially when circulating glucose concentrations are low [14, 77â€“81]. In mammalian cells, the 
mitochondria, peroxisomes, and cytochromes mediate 
FAO [78, 82]. Entry of fatty acids into the mitochondria 
relies on carnitine palmitoyltransferase 1 (CPT1) situated 
in the outer mitochondrial membrane [80], but as the mitochondria lack the ability to oxidize very long chain fatty 
acids [79], these are preferably metabolized via peroxisomal Î²-oxidation. In case of lipid overloadâ€”such as in 
NAFLDâ€”Ï‰-oxidation in the cytochromes also contributes [78]. However, these processes generate considerable amounts of reactive oxygen species (ROS), oxidative 
stress, and toxic dicarboxylic acids, potentially promoting 
infammation and disease progression [78] (Fig.Â 3).
Activation of PPARÎ± induces the transcription of a 
range of genes related to FAO in the mitochondria, peroxisomes, and cytochromes, thereby reducing hepatic 
lipid levels [77, 80, 81, 83]. Knockout of PPARÎ± in ob/
ob mice results in hepatic steatosis, supporting a role of 
PPARÎ± in the regulation of hepatic lipid metabolism [84]. 
A 24Â h fasting period of WT or ob/ob mice, upregulated 
PPARÎ± and PPARÎ±-target genes related to mitochondrial 
(medium- and long-chain acyl-CoA dehydrogenases), peroxisomal (acyl-CoA oxidase (ACOX) 1 and enoyl-CoA 
hydratase), and cytochrome-mediated (CYP4A1 and 
CYP4A3) FAO [85]. This response was less pronounced 
in PPARÎ± knockout animals and coincided with hepatic 
steatosis, again emphasizing the critical role of PPARÎ± in 
promoting FAO and preventing hepatic lipid accumulation [85]. In humans, hepatic PPARÎ± levels did not difer 
between patients with steatosis (n=16) and healthy controls (n = 8) [19]. However, PPARÎ± was downregulated 
in patients with NASH compared to patients with steatosis and healthy controls [75, 86], and the expression of 
PPARÎ± decreased with increasing NAFLD activity score 
and fbrosis stage [86]. In addition, a longitudinal analysis after a 1-year follow-up associated increased PPARÎ± 
with histological improvements in NASH [86]. Decreased 
PPARÎ± in NASH also enhanced the DNA-binding capacity 
of c-Jun N-terminal kinase 1 (JNK1) and nuclear factor 
kappa-light-chain enhancer of activated B cells (NF-ÎºB) 
leading to increased hepatic infammation [87]. Thus, 
PPARÎ± expression may be related to several aspects of 
NASH progression, modulating not only lipid homeostasis, but infammation as well.
The expected consequence of hepatic lipid accumulation would be increased FAO. However, studies of 
FAO in patients with steatosis or NASH are conficting, 
reporting enhanced [88â€“92], unchanged [93], or decreased 
FAO [94]. The broad range of hepatic states covered by 
the term NAFLD makes it difcult to compare studies 
directly, and oxidation of fatty acids may difer based on 
the severity of the disease. Furthermore, FAO capacities 
may vary inter-individually rendering some subjects more 
susceptible to NAFLD. Indeed, rats selectively bred for 
low intrinsic aerobic capacity display decreased mitochondrial FAO and were predisposed to diet-induced hepatic 
steatosis [95]. Expression of genes related to mitochondrial and peroxisomal Î²-oxidation was higher in patients 
with more severe steatosis (n =11) compared to patients 
with less severe steatosis (n = 21) or non-steatotic controls (n = 16) [96]. Î²-Oxidation, measured indirectly as 
plasma Î²-hydroxybutyrate levels, was higher in patients 
with NASH (n=6) compared to steatosis (n=6) or normal 
controls (n=6) [90]. Increased FAO may be an adaptive 
response in patients with NAFLD attempting to reduce 
the lipid overload and lipotoxicity, but also produces ROS 
and excessive FAO may overwhelm the capacity of the 
anti-oxidant defense system and induce oxidative stress. 
Accordingly, hepatic oxidative stress and changes in mitochondrial ultrastructure were increased alongside FAO in 
patients with NASH [90]. Glutathione, glutathione peroxidase, and superoxide dismutase were decreased in liver 
biopsies from NAFLD patients and in mitochondria from 
animal models of NAFLD [82, 87], closing the loop on 
a vicious cycle in which the diminishing capacity of the 
antioxidant defense system is continuously being depleted 
by rising ROS levels. In NASH patients (n= 10), oxidative DNA damage was signifcantly increased compared 
to healthy controls (n = 16) despite similar rates of FAO 
following an intravenous infusion of lipids, suggesting 
increased susceptibility to oxidative stress in these patients 
[89].
Lipid oxidation and oxidative damage to mitochondrial 
DNA further diminish mitochondrial function, establishing a self-perpetuating vicious cycle to exacerbate mitochondrial dysfunction and oxidative stress [80]. Decreased 
activity of the mitochondrial respiratory chain was reported 
in overweight/obese patients with NASH compared to 
controls [97, 98], and alterations in mitochondrial ultrastructure have been observed prior to NAFLD development in the Otsuka Longâ€“Evans Tokushima Fatty rat [99] 
as well as in patients with steatosis preceding progression 
to NASH [100]. The decrease in mitochondrial function 
may result in the utilization of alternative FAO pathways. 
Mice heterozygous for mitochondrial trifunctional protein 
have compromised mitochondrial Î²-oxidation and develop 
hepatic steatosis alongside a compensatory upregulation of 
CYP2E1-facilitated FAO and oxidative stress [101, 102]. In 
NASH patients, hepatic CYP2E1 activity was increased and 
expression specifcally localized to steatotic areas compared 

3320 D.Â H.Â Ipsen et al.
1 3
to patients with steatosis and healthy controls [103â€“105]. 
CYP2E1 activity correlated with disease severity suggesting 
an involvement of CYP2E1 in FAO particularly during later 
disease stages, i.e., NASH [104]. In contrast, other studies 
have reported no diference in CYP2E1 expression between 
patients with NASH (n=30) and those with only steatosis 
(n=10) [106]. Thus, enhanced CYP2E1 did not diferentiate 
bland steatosis from NASH, but could still play a role in disease progression. In agreement with enhanced cytochromemediated FAO, increased CYP4A11â€”another key fatty acid 
metabolizing enzyme located in the cytochromesâ€”has been 
reported in patients with NAFLD [45, 107]. Increased FAO 
in cytochromes may then be an important event in steatosis 
and NASH, with the excessive amount of ROS produced by 
the CYP enzymes exacerbating hepatic oxidative stress and 
consequently worsening liver damage.
The last of the three organelles important to fatty acid 
metabolism and hepatic lipid homeostasis is the peroxisomes. Targeting this system, either by hepatocyte-specifc 
knockout of peroxisomes or by defciency in ACOX (which 
catalyzes the initial step in peroxisomal FAO), results in 
hepatic lipid accumulation and fbrosis, oxidative stress, 
and infammation, emphasizing the role of peroximal FAO 
in NAFLD and NASH [108]. A massive upregulation of 
PPARÎ± was observed during ageing in ACOX defcient 
mice, suggesting ACOX substrates as endogenous activators of PPARÎ± [109]. ACOX and branch-chained acyl-CoA 
oxidase (another peroxisomal enzyme involved in FAO) 
mRNA levels were higher in patients with NAFLD compared to controls, indicating that peroxisomal FAO upregulation may be a compensatory response aiming to resolve 
the progressing steatosis in NAFLD [45, 107]. However, 
similar to Ï‰-oxidation in the cytochromes, the peroxisomes 
generate ROS as they oxidize fatty acids, and likewise, the 
peroxisomes may induce oxidative stress and promote disease progression [83].
In summary, the current data on FAO in NAFLD are 
conficting, but even in studies suggesting enhanced FAO, 
augmented oxidation of fatty acids appear inadequate in 
clearing the liver of lipids. FAO in dysfunctional mitochondriaâ€”a characteristic of NAFLDâ€”produces excessive ROS 
and may also favor the utilization of the peroxisomes and 
cytochromes for FAO. This ultimately facilitates disease 
progression by inducing oxidative stress and infammation.
Lipid export
In addition to FAO, export of triglycerides is the only way 
to reduce hepatic lipid content [68]. Due to their hydrophobic nature, fatty acids can only be exported from the liver 
after being packed into water-soluble VLDL particles alongside cholesterol, phospholipids, and apolipoproteins [110]. 
VLDL particles are formed in the endoplasmic reticulum, 
where apolipoprotein B100 (apoB100) is lipidated in a 
process catalyzed by the enzyme microsomal triglyceride 
transfer protein (MTTP). The nascent VLDL particle is then 
transferred to the Golgi apparatus, and during this process, 
the particle is further lipidated until a mature VLDL particle 
is formed [111]. While one molecule of apoB100 is associated with each VLDL particle, and is required for VLDL 
export, the triglyceride content of the VLDL particle can 
vary considerably [9, 110]. Consequently, apoB100 and 
MTTP are key components in hepatic VLDL secretion and 
in maintaining hepatic lipid homeostasis. As such, hepatic 
steatosis, secondary to compromised triglyceride export, 
is common in patients with genetic defects in the apoB or 
MTTP gene (hypobetalipoproteinemia and abetaproteinemia, respectively) [112, 113]. Although moderate exposure 
to fatty acids increased apoB100 secretion, prolonged exposure leads to ER stress and posttranslational degradation of 
apoB100, and consequently decreased apoB100 secretion, 
both inÂ vivo and inÂ vitro hereby linking ER stress to NAFLD 
progression through apoB100 inhibition [114, 115] (Fig.Â 3). 
MTTP gene transcription is positively regulated by PPARÎ± 
and increased MTTP expression is paralleled by a change in 
apoB100 secretion, but a paradoxical decrease in circulating 
triglycerides in mice [116]. This could be due to a PPARÎ±mediated inhibition of apoCIII, promoting the clearance of 
apoB100-associated lipoproteins [116]. Notably, whereas 
PPARÎ± agonism increases plasma HDL in humans, this is 
not the case in most applied rat and mouse models, as they 
lack the PPAR response element in the promotor region of 
ApoA1 (the major apolipoprotein of HDL); in fact, HDL 
may even be decreased in response to PPARÎ± these species 
[117]. Thus, PPARÎ± not only exerts its catabolic efect via 
FAO, but also through the regulation of lipoprotein metabolism. Conversely, both apoB100 and MTTP are negatively 
regulated by insulin, which reduces hepatic lipid export by 
inducing apoB100 degradation and suppressing MTTP synthesis [111]. High insulin levels in the post-prandial state 
decrease hepatic VLDL production, favoring chylomicronmediated delivery of dietary lipids to the periphery [111], 
but the selective hepatic insulin resistance in patients with 
NAFLD allows insulin to stimulate DNL without inhibiting 
VLDL production [118]. VLDL secretion was increased in 
patients with NAFLD [65, 110, 119] and liver triglyceride 
content was directly associated with VLDL-TG secretion 
rates [65, 66, 110, 119]. However, while VLDL-TG export 
increased with intrahepatic lipid content, secretion plateaued when hepatic fat content exceeded 10%, surpassing 
the compensatory capacity to prevent increasing hepatic 
lipid accumulation [110]. Despite higher VLDL-TG secretion in patients with hepatic steatosis compared to healthy 
individuals, VLDL-apoB100 secretion was unchanged, 
suggesting that NAFLD patients do not secrete additional, 

Molecular mechanisms ofÂ hepatic lipid accumulation inÂ non-alcoholic fatty liver disease 3321
1 3
but instead larger and more triglyceride-rich, VLDL particles [110]. However, very large VLDL particles cannot 
be secreted if their diameter exceeds that of the sinusoidal 
endothelial pores, and this limitation may ultimately result 
in lipid retention and NAFLD [120]. Failure to increase the 
number of secreted VLDL particles could indicate suboptimal apoB100 levels as a precipitating factor in NAFLD, and 
while mRNA levels of apoB100 and MTTP was found to be 
higher in patients with NAFLD compared to controls [35, 
121], apoB100 synthesis rates were lower in patients with 
NASH (n=7) compared to lean (n=7) or BMI-matched 
obese (n = 7) controls without NASH [122]. Likewise, 
hepatic mRNA levels of apoB100 and MTTP and serum 
VLDL-TG were higher in patients with steatosis (n=51) 
compared to patients with NASH (n=53), marking deterioration of VLDL assembly and export as important in the 
progression from steatosis to NASH [75]. NAFLD patients 
with more advanced steatosis (>30%) had decreased MTTP 
levels compared to healthy controls, suggesting that lipid 
export may also become compromised directly by the accumulation of substantial amounts of intracellular lipids [35]. 
Consequently, vector-mediated overexpression of MTTP in 
the Fatty Liver Shionogi mice decreased liver triglycerides 
and improved NASH [123]. Given the efect of PPARÎ± on 
lipoprotein metabolism, it could be speculated that declining 
PPARÎ± levels with NAFLD progression [75, 86] contribute to lower MTTP levels and apoB100 secretion rates. In 
contrast, similar expression levels of MTTP and apoB100 
between patients with steatosis, NASH, and healthy controls 
have also been reported, denoting the considerable disease 
heterogeneity associated with NAFLD [124].
Despite the variation between studies, lipid export in 
NAFLD seems to be biphasic, initially increasing followed 
by a plateau or even decrease. The diminished export results 
in hepatic lipid overload and subsequent intracellular lipid 
accumulation, leading to steatosis, lipotoxicity, and liver 
damage, and promoting disease progression and fbrosis.
Preâ€‘clinical models andÂ current clinical 
management
There is currently no approved pharmacological treatment 
for NAFLD. A major limiting factor in the development of 
new treatments is the lack of predictive pre-clinical models 
that accurately refect human disease with regard to liver 
histology, pathophysiology, and metabolic abnormalities. 
The available animal models can be characterized as dietary, 
genetic or as a combination of these two. However, as mutations are rarely the cause of human NAFLD, this section will 
highlight some of the most commonly applied dietary models. These models attempt to replicate the unhealthy Western 
dietary pattern associated with NAFLD in humans, which 
are often high in fat, sugar, and cholesterol. However, to 
ensure translatability, it is important to maintain physiologically relevant levels of dietary macro- and micronutrients.
The methionine and choline-defcient diet (commonly 
applied in mice and rats) and choline-defcient L-aminodefned diet rapidly induce NASH, but fail to reproduce the 
pathophysiological response corresponding to clinical observations [125, 126]. Atherogenic diets can induce NASH 
and fbrosis, but the exceedingly high levels of cholesterol 
(1â€“2%) and the inclusion of cholic acid difer from the clinical situation and may even improve glucose tolerance and 
insulin sensitivity [127â€“129]. The addition of a high-fat 
component returns these to, at least, normal glucose/insulin 
levels [127]. Noticeably, a major limitation of the current 
models utilizing Western diets, not employing micronutrient defciency or abnormally high amounts of cholesterol, is 
the absence of progressive, advanced hepatic fbrosis [129]. 
Using a human-like Western diet, the diet-induced animal 
model of non-alcoholic fatty liver disease (DIAMOND) 
mouse was developed as a promising pre-clinical model 
resembling human liver histology, pathophysiology, metabolic signatures, and advanced fbrosis as well as hepatocellular carcinoma after 52Â weeks [130]. Unlike mice and 
rats, guinea pigs naturally resemble the human lipoprotein 
profle and develop human-like NASH histopathology, dyslipidemia, and hepatic oxidative stress when fed a Western 
diet [131â€“133]. Advanced hepatic fbrosis develops after 
20â€“24Â weeks [132], allowing interventions to be evaluated 
on advanced disease stages within a relatively short time 
frame. Nevertheless, while animals represent a tool to study 
NAFLD and NASH, it is unlikely that any single animal 
model will refect all aspects of human NASH and researchers must critically select the model(s) best suited for the 
subject of investigation.
Diet and lifestyle interventions are mainstay in the treatment of NAFLD, and weight-lossâ‰¥7% confers histological 
improvements of NASH [134]. However, lifestyle interventions are notoriously difcult to maintain [135], suggesting that some patients may beneft from pharmacological 
therapy. When validated in randomized clinical trials, only a 
few drugs have shown efcacy on NASH liver histology and/
or fbrosis. These include vitamin E, pioglitazone (PPARÎ³ 
agonist), obeticholic acid (farensoid X receptor agonist), 
cenicriviroc (CCR2/CCR5 antagonist), selonsertib (apoptosis signal-regulating kinase 1 inhibitor), and liraglutide 
(glucagon-like peptide 1 analogue) [136â€“141]. However, 
adverse efects may limit the treatment potential, e.g., glitazones are associated with phenotypical weight gain [136] 
and obeticholic acidÂ induced pruritus and elevated LDL-C 
[137], the latter a potential concern in patients already at risk 
for cardiovascular disease. Cenicrivirocâ€”despite not meeting its primary endpoint of NAFLD activity score improvementâ€”[138] and obeticholic acid [137] were both able to 

3322 D.Â H.Â Ipsen et al.
1 3
improve hepatic fbrosis, and were currently undergoing 
phase III investigation. In addition, promising results have 
been reported for several phase II clinical trials and additional trials are currently ongoing, refecting the growing 
research efort in developing novel treatments for NASH. 
Given the heterogenic nature of NAFLD, targeting metabolic, anti-infammatory, or anti-fbrotic disease pathways 
simultaneously may exert an additive or synergistic efect 
and combination therapy may prove to be a an important 
tool in the future development of pharmacological treatment 
options.
Conclusion
In NAFLD, hepatic lipid acquisitionâ€”mediated by increased 
fatty acid uptake and DNLâ€”is enhanced despite the presence of steatosis. Lipid disposal may be increased, but is 
ultimately incapable of counteracting the growing intrahepatic fat deposition. While lipid export is enhanced in early 
disease stages, it decreases or plateaus with disease severity as hepatocyte metabolism becomes increasingly compromised. Eforts to reduce lipid levels can even promote 
disease progression, as FAO may induce oxidative stress, 
exhausting antioxidant competences and promoting damage 
to cellular organelles and DNA. The molecular mechanisms 
governing hepatic lipid homeostasis and the counter regulatory mechanisms related to a chronic lipid overload and 
NAFLD are both complex and tightly interconnected. Thus, 
any intervention targeting one or more pathway is likely to 
have consequences on multiple cellular signaling pathways. 
This, as well as inter-individual diferences, should be taken 
into careful consideration when developing future treatment 
options for NAFLD.
Compliance with ethical standards
Conflict of interest The authors declare that they have no confict of 
interest.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativeco
mmons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry 
L, Wymer M (2016) Global epidemiology of nonalcoholic 
fatty liver diseaseâ€”meta-analytic assessment of prevalence, 
incidence, and outcomes. Hepatology 64:73â€“84. https://doi.
org/10.1002/hep.28431
2. Hojland Ipsen D, Tveden-Nyborg P, Lykkesfeldt J (2016) Normal 
weight dyslipidemia: is it all about the liver? Obesity (Silver 
Spring) 24:556â€“567. https://doi.org/10.1002/oby.21443
3. Wattacheril J, Sanyal AJ (2016) Lean NAFLD: an underrecognized outlier. Curr Hepatol Rep 15:134â€“139. https://doi.
org/10.1007/s11901-016-0302-1
4. Adams LA, Anstee QM, Tilg H, Targher G (2017) Non-alcoholic fatty liver disease and its relationship with cardiovascular 
disease and other extrahepatic diseases. Gut 66:1138â€“1153. 
https://doi.org/10.1136/gutjnl-2017-313884
5. Pais R, Barritt AS, Calmus Y, Scatton O, Runge T, Lebray P, 
Poynard T, Ratziu V, Conti F (2016) NAFLD and liver transplantation: current burden and expected challenges. J Hepatol 
65:1245â€“1257. https://doi.org/10.1016/j.jhep.2016.07.033
6. Loomba R, Chalasani N (2015) The hierarchical model 
of NAFLD: prognostic significance of histologic features 
in NASH. Gastroenterology 149:278â€“281. https://doi.
org/10.1053/j.gastro.2015.06.016
7. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, 
Anstee QM (2015) Evidence of NAFLD progression from 
steatosis to fbrosing-steatohepatitis using paired biopsies: 
implications for prognosis and clinical management. J Hepatol 
62:1148â€“1155. https://doi.org/10.1016/j.jhep.2014.11.034
8. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba 
R (2015) Fibrosis progression in nonalcoholic fatty liver vs 
nonalcoholic steatohepatitis: a systematic review and metaanalysis of paired-biopsy studies. Clin Gastroenterol Hepatol 
13:643â€“654, e641â€“649 (quiz e639â€“640)
9. Fabbrini E, Magkos F (2015) Hepatic steatosis as a marker 
of metabolic dysfunction. Nutrients 7:4995â€“5019. https://doi.
org/10.3390/nu7064995
10. Ipsen DH, Tveden-Nyborg P, Lykkesfeldt J (2016) Dyslipidemia: obese or not obeseâ€”that is not the question. Curr Obes 
Rep 5:405â€“412. https://doi.org/10.1007/s13679-016-0232-9
11. Nguyen P, Leray V, Diez M, Serisier S, Le Blocâ€™h J, Siliart 
B, Dumon H (2008) Liver lipid metabolism. J Anim Physiol Anim Nutr (Berl) 92:272â€“283. https://doi.org/10.111
1/j.1439-0396.2007.00752.x
12. Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, 
Trauner M, Canbay A (2012) The interaction of hepatic lipid 
and glucose metabolism in liver diseases. J Hepatol 56:952â€“
964. https://doi.org/10.1016/j.jhep.2011.08.025
13. Mashek DG (2013) Hepatic fatty acid trafcking: multiple 
forks in the road. Adv Nutr 4:697â€“710. https://doi.org/10.3945/
an.113.004648
14. Koo SH (2013) Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin Mol Hepatol 
19:210â€“215. https://doi.org/10.3350/cmh.2013.19.3.210
15. Falcon A, Doege H, Fluitt A, Tsang B, Watson N, Kay MA, 
Stahl A (2010) FATP2 is a hepatic fatty acid transporter and 
peroxisomal very long-chain acyl-CoA synthetase. Am J Physiol Endocrinol Metab 299:E384â€“E393. https://doi.org/10.1152/
ajpendo.00226.2010
16. Doege H, Baillie RA, Ortegon AM, Tsang B, Wu Q, Punreddy 
S, Hirsch D, Watson N, Gimeno RE, Stahl A (2006) Targeted 
deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis. Gastroenterology 
130:1245â€“1258. https://doi.org/10.1053/j.gastro.2006.02.006
17. Doege H, Grimm D, Falcon A, Tsang B, Storm TA, Xu H, 
Ortegon AM, Kazantzis M, Kay MA, Stahl A (2008) Silencing of hepatic fatty acid transporter protein 5 inÂ vivo reverses 
diet-induced non-alcoholic fatty liver disease and improves 
hyperglycemia. J Biol Chem 283:22186â€“22192. https://doi.
org/10.1074/jbc.M803510200

Molecular mechanisms ofÂ hepatic lipid accumulation inÂ non-alcoholic fatty liver disease 3323
1 3
18. Zhu L, Baker SS, Liu W, Tao MH, Patel R, Nowak NJ, Baker 
RD (2011) Lipid in the livers of adolescents with nonalcoholic 
steatohepatitis: combined efects of pathways on steatosis. 
Metabolism 60:1001â€“1011. https://doi.org/10.1016/j.metab
ol.2010.10.003
19. Westerbacka J, Kolak M, Kiviluoto T, Arkkila P, Siren J, Hamsten A, Fisher RM, Yki-Jarvinen H (2007) Genes involved in 
fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and infammation are overexpressed in 
the human fatty liver of insulin-resistant subjects. Diabetes 
56:2759â€“2765. https://doi.org/10.2337/db07-0156
20. Auinger A, Valenti L, Pfeufer M, Helwig U, Herrmann J, Fracanzani AL, Dongiovanni P, Fargion S, Schrezenmeir J, Rubin D 
(2010) A promoter polymorphism in the liver-specifc fatty acid 
transport protein 5 is associated with features of the metabolic 
syndrome and steatosis. Horm Metab Res 42:854â€“859. https://
doi.org/10.1055/s-0030-1267186
21. Silverstein RL, Febbraio M (2009) CD36, a scavenger receptor 
involved in immunity, metabolism, angiogenesis, and behavior. 
Sci Signal 2:re3. https://doi.org/10.1126/scisignal.272re3
22. Koonen DP, Jacobs RL, Febbraio M, Young ME, Soltys CL, Ong 
H, Vance DE, Dyck JR (2007) Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced 
obesity. Diabetes 56:2863â€“2871. https://doi.org/10.2337/
db07-0907
23. Wilson CG, Tran JL, Erion DM, Vera NB, Febbraio M, Weiss EJ 
(2016) Hepatocyte-specifc disruption of CD36 attenuates fatty 
liver and improves insulin sensitivity in HFD-fed mice. Endocrinology 157:570â€“585. https://doi.org/10.1210/en.2015-1866
24. Greco D, Kotronen A, Westerbacka J, Puig O, Arkkila P, Kiviluoto T, Laitinen S, Kolak M, Fisher RM, Hamsten A, Auvinen P, 
Yki-Jarvinen H (2008) Gene expression in human NAFLD. Am 
J Physiol Gastrointest Liver Physiol 294:G1281â€“G1287. https://
doi.org/10.1152/ajpgi.00074.2008
25. Miquilena-Colina ME, Lima-Cabello E, Sanchez-Campos S, 
Garcia-Mediavilla MV, Fernandez-Bermejo M, Lozano-Rodriguez T, Vargas-Castrillon J, Buque X, Ochoa B, Aspichueta P, 
Gonzalez-Gallego J, Garcia-Monzon C (2011) Hepatic fatty acid 
translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic 
steatohepatitis and chronic hepatitis C. Gut 60:1394â€“1402. https
://doi.org/10.1136/gut.2010.222844
26. Auguet T, Berlanga A, Guiu-Jurado E, Martinez S, Porras JA, 
Aragones G, Sabench F, Hernandez M, Aguilar C, Sirvent JJ, 
Del Castillo D, Richart C (2014) Altered fatty acid metabolismrelated gene expression in liver from morbidly obese women with 
non-alcoholic fatty liver disease. Int J Mol Sci 15:22173â€“22187. 
https://doi.org/10.3390/ijms151222173
27. Qiu Y, Liu S, Chen HT, Yu CH, Teng XD, Yao HT, Xu GQ 
(2013) Upregulation of caveolin-1 and SR-B1 in mice with 
non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int 
12:630â€“636
28. Brunt EM (2009) Histopathology of non-alcoholic fatty liver 
disease. Clin Liver Dis 13:533â€“544. https://doi.org/10.1016/j.
cld.2009.07.008
29. Asterholm IW, Mundy DI, Weng J, Anderson RG, Scherer PE 
(2012) Altered mitochondrial function and metabolic infexibility 
associated with loss of caveolin-1. Cell Metab 15:171â€“185. https
://doi.org/10.1016/j.cmet.2012.01.004
30. Li M, Chen D, Huang H, Wang J, Wan X, Xu C, Li C, Ma H, Yu 
C, Li Y (2017) Caveolin1 protects against diet induced hepatic 
lipid accumulation in mice. PLoS One 12:e0178748. https://doi.
org/10.1371/journal.pone.0178748
31. Wang G, Bonkovsky HL, de Lemos A, Burczynski FJ (2015) 
Recent insights into the biological functions of liver fatty 
acid binding protein 1. J Lipid Res 56:2238â€“2247. https://doi.
org/10.1194/jlr.R056705
32. Wolfrum C, Borrmann CM, Borchers T, Spener F (2001) Fatty 
acids and hypolipidemic drugs regulate peroxisome proliferatoractivated receptors alphaâ€”and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the 
nucleus. Proc Natl Acad Sci USA 98:2323â€“2328. https://doi.
org/10.1073/pnas.051619898
33. Newberry EP, Xie Y, Kennedy S, Han X, Buhman KK, Luo J, 
Gross RW, Davidson NO (2003) Decreased hepatic triglyceride 
accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene. J Biol Chem 
278:51664â€“51672. https://doi.org/10.1074/jbc.M309377200
34. Martin GG, Atshaves BP, Huang H, McIntosh AL, Williams 
BJ, Pai PJ, Russell DH, Kier AB, Schroeder F (2009) Hepatic 
phenotype of liver fatty acid binding protein gene-ablated 
mice. Am J Physiol Gastrointest Liver Physiol 297:G1053â€“
G1065. https://doi.org/10.1152/ajpgi.00116.2009
35. Higuchi N, Kato M, Tanaka M, Miyazaki M, Takao S, Kohjima 
M, Kotoh K, Enjoji M, Nakamuta M, Takayanagi R (2011) 
Efects of insulin resistance and hepatic lipid accumulation on 
hepatic mRNA expression levels of apoB, MTP and L-FABP in 
non-alcoholic fatty liver disease. Exp Ther Med 2:1077â€“1081. 
https://doi.org/10.3892/etm.2011.328
36. Charlton M, Viker K, Krishnan A, Sanderson S, Veldt B, Kaalsbeek AJ, Kendrick M, Thompson G, Que F, Swain J, Sarr 
M (2009) Diferential expression of lumican and fatty acid 
binding protein-1: new insights into the histologic spectrum 
of nonalcoholic fatty liver disease. Hepatology 49:1375â€“1384. 
https://doi.org/10.1002/hep.22927
37. Listenberger LL, Han X, Lewis SE, Cases S, Farese RV Jr, 
Ory DS, Schafer JE (2003) Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad 
Sci USA 100:3077â€“3082. https://doi.org/10.1073/pnas.06305
88100
38. Diraison F, Moulin P, Beylot M (2003) Contribution of hepatic 
de novo lipogenesis and reesterifcation of plasma non esterifed 
fatty acids to plasma triglyceride synthesis during non-alcoholic 
fatty liver disease. Diabetes Metab 29:478â€“485
39. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ (2014) 
Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 
146:726â€“735. https://doi.org/10.1053/j.gastro.2013.11.049
40. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt 
MD, Parks EJ (2005) Sources of fatty acids stored in liver and 
secreted via lipoproteins in patients with nonalcoholic fatty liver 
disease. J Clin Investig 115:1343â€“1351. https://doi.org/10.1172/
JCI23621
41. Sanders FW, Grifn JL (2016) De novo lipogenesis in the liver 
in health and disease: more than just a shunting yard for glucose. 
Biol Rev Camb Philos Soc 91:452â€“468. https://doi.org/10.1111/
brv.12178
42. Eberle D, Hegarty B, Bossard P, Ferre P, Foufelle F (2004) 
SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 86:839â€“848. https://doi.org/10.1016/j.bioch
i.2004.09.018
43. Yamashita H, Takenoshita M, Sakurai M, Bruick RK, Henzel WJ, 
Shillinglaw W, Arnot D, Uyeda K (2001) A glucose-responsive 
transcription factor that regulates carbohydrate metabolism in 
the liver. Proc Natl Acad Sci USA 98:9116â€“9121. https://doi.
org/10.1073/pnas.161284298
44. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, 
Goldstein JL (1997) Isoform 1c of sterol regulatory element 
binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Investig 99:846â€“854. 
https://doi.org/10.1172/JCI119248

3324 D.Â H.Â Ipsen et al.
1 3
45. Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto 
T, Fujino T, Yada M, Yada R, Harada N, Takayanagi R, Nakamuta M (2007) Re-evaluation of fatty acid metabolism-related 
gene expression in nonalcoholic fatty liver disease. Int J Mol 
Med 20:351â€“358. https://doi.org/10.3892/ijmm.20.3.351
46. Liang G, Yang J, Horton JD, Hammer RE, Goldstein JL, Brown 
MS (2002) Diminished hepatic response to fasting/refeeding 
and liver X receptor agonists in mice with selective defciency 
of sterol regulatory element-binding protein-1c. J Biol Chem 
277:9520â€“9528. https://doi.org/10.1074/jbc.M111421200
47. Uyeda K, Repa JJ (2006) Carbohydrate response element binding 
protein, ChREBP, a transcription factor coupling hepatic glucose 
utilization and lipid synthesis. Cell Metab 4:107â€“110. https://doi.
org/10.1016/j.cmet.2006.06.008
48. Iizuka K, Bruick RK, Liang G, Horton JD, Uyeda K (2004) 
Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc 
Natl Acad Sci USA 101:7281â€“7286. https://doi.org/10.1073/
pnas.0401516101
49. Dentin R, Benhamed F, Hainault I, Fauveau V, Foufelle F, 
Dyck JR, Girard J, Postic C (2006) Liver-specifc inhibition of 
ChREBP improves hepatic steatosis and insulin resistance in 
ob/ob mice. Diabetes 55:2159â€“2170. https://doi.org/10.2337/
db06-0200
50. Zhang D, Tong X, VanDommelen K, Gupta N, Stamper K, Brady 
GF, Meng Z, Lin J, Rui L, Omary MB, Yin L (2017) Lipogenic transcription factor ChREBP mediates fructose-induced 
metabolic adaptations to prevent hepatotoxicity. J Clin Investig 
127:2855â€“2867. https://doi.org/10.1172/JCI89934
51. Ducheix S, Vegliante MC, Villani G, Napoli N, Sabba C, Moschetta A (2016) Is hepatic lipogenesis fundamental for NAFLD/
NASH? A focus on the nuclear receptor coactivator PGC-1beta. 
Cell Mol Life Sci 73:3809â€“3822. https://doi.org/10.1007/s0001
8-016-2331-x
52. Benhamed F, Denechaud PD, Lemoine M, Robichon C, Moldes 
M, Bertrand-Michel J, Ratziu V, Serfaty L, Housset C, Capeau J, 
Girard J, Guillou H, Postic C (2012) The lipogenic transcription 
factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Investig 122:2176â€“2194. https
://doi.org/10.1172/JCI41636
53. Higuchi N, Kato M, Shundo Y, Tajiri H, Tanaka M, Yamashita 
N, Kohjima M, Kotoh K, Nakamuta M, Takayanagi R, Enjoji 
M (2008) Liver X receptor in cooperation with SREBP-1c is a 
major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol Res 38:1122â€“1129. https://doi.org/10.1111/j.1872-
034X.2008.00382.x
54. Perfeld JW 2nd, Ortinau LC, Pickering RT, Ruebel ML, Meers 
GM, Rector RS (2013) Altered hepatic lipid metabolism contributes to nonalcoholic fatty liver disease in leptin-defcient Ob/Ob 
mice. J Obes 2013:296537. https://doi.org/10.1155/2013/29653
7
55. Xie Z, Li H, Wang K, Lin J, Wang Q, Zhao G, Jia W, Zhang Q 
(2010) Analysis of transcriptome and metabolome profles alterations in fatty liver induced by high-fat diet in rat. Metabolism 
59:554â€“560. https://doi.org/10.1016/j.metabol.2009.08.022
56. Postic C, Girard J (2008) Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from 
genetically engineered mice. J Clin Investig 118:829â€“838. https
://doi.org/10.1172/JCI34275
57. Dorn C, Riener MO, Kirovski G, Saugspier M, Steib K, Weiss 
TS, Gabele E, Kristiansen G, Hartmann A, Hellerbrand C (2010) 
Expression of fatty acid synthase in nonalcoholic fatty liver disease. Int J Clin Exp Pathol 3:505â€“514
58. Mao J, DeMayo FJ, Li H, Abu-Elheiga L, Gu Z, Shaikenov TE, 
Kordari P, Chirala SS, Heird WC, Wakil SJ (2006) Liver-specifc 
deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without afecting glucose homeostasis. Proc 
Natl Acad Sci USA 103:8552â€“8557. https://doi.org/10.1073/
pnas.0603115103
59. Savage DB, Choi CS, Samuel VT, Liu ZX, Zhang D, Wang A, 
Zhang XM, Cline GW, Yu XX, Geisler JG, Bhanot S, Monia BP, 
Shulman GI (2006) Reversal of diet-induced hepatic steatosis and 
hepatic insulin resistance by antisense oligonucleotide inhibitors 
of acetyl-CoA carboxylases 1 and 2. J Clin Investig 116:817â€“824. 
https://doi.org/10.1172/JCI27300
60. Chakravarthy MV, Pan Z, Zhu Y, Tordjman K, Schneider JG, 
Coleman T, Turk J, Semenkovich CF (2005) â€œNewâ€ hepatic fat 
activates PPARalpha to maintain glucose, lipid, and cholesterol 
homeostasis. Cell Metab 1:309â€“322. https://doi.org/10.1016/j.
cmet.2005.04.002
61. Li ZZ, Berk M, McIntyre TM, Feldstein AE (2009) Hepatic lipid 
partitioning and liver damage in nonalcoholic fatty liver disease: 
role of stearoyl-CoA desaturase. J Biol Chem 284:5637â€“5644. 
https://doi.org/10.1074/jbc.M807616200
62. Jiang G, Li Z, Liu F, Ellsworth K, Dallas-Yang Q, Wu M, Ronan 
J, Esau C, Murphy C, Szalkowski D, Bergeron R, Doebber T, 
Zhang BB (2005) Prevention of obesity in mice by antisense 
oligonucleotide inhibitors of stearoyl-CoA desaturase-1. J Clin 
Investig 115:1030â€“1038. https://doi.org/10.1172/JCI23962
63. Shulman GI (2014) Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 371:1131â€“
1141. https://doi.org/10.1056/NEJMra1011035
64. Kitade H, Chen G, Ni Y, Ota T (2017) nonalcoholic fatty liver 
disease and insulin resistance: new insights and potential new 
treatments. Nutrients 9:387. https://doi.org/10.3390/nu9040387
65. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad 
NA, Patterson BW, Okunade A, Klein S (2009) Intrahepatic 
fat, not visceral fat, is linked with metabolic complications of 
obesity. Proc Natl Acad Sci USA 106:15430â€“15435. https://doi.
org/10.1073/pnas.0904944106
66. Magkos F, Fabbrini E, Mohammed BS, Patterson BW, Klein S 
(2010) Increased whole-body adiposity without a concomitant 
increase in liver fat is not associated with augmented metabolic 
dysfunction. Obesity (Silver Spring) 18:1510â€“1515. https://doi.
org/10.1038/oby.2010.90
67. Stefan N, Staiger H, Haring HU (2011) Dissociation between 
fatty liver and insulin resistance: the role of adipose triacylglycerol lipase. Diabetologia 54:7â€“9. https://doi.org/10.1007/s0012
5-010-1938-y
68. Perry RJ, Samuel VT, Petersen KF, Shulman GI (2014) The role 
of hepatic lipids in hepatic insulin resistance and type 2 diabetes. 
Nature 510:84â€“91. https://doi.org/10.1038/nature13478
69. Monetti M, Levin MC, Watt MJ, Sajan MP, Marmor S, Hubbard 
BK, Stevens RD, Bain JR, Newgard CB, Farese RV Sr, Hevener 
AL, Farese RV Jr (2007) Dissociation of hepatic steatosis and 
insulin resistance in mice overexpressing DGAT in the liver. Cell 
Metab 6:69â€“78. https://doi.org/10.1016/j.cmet.2007.05.005
70. Samuel VT, Liu ZX, Wang A, Beddow SA, Geisler JG, Kahn M, 
Zhang XM, Monia BP, Bhanot S, Shulman GI (2007) Inhibition 
of protein kinase Cepsilon prevents hepatic insulin resistance in 
nonalcoholic fatty liver disease. J Clin Investig 117:739â€“745. 
https://doi.org/10.1172/JCI30400
71. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, 
Bhanot S, Monia BP, Li YX, Diehl AM (2007) Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates 
liver damage and fbrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45:1366â€“1374. https://doi.org/10.1002/
hep.21655
72. Ter Horst KW, Gilijamse PW, Versteeg RI, Ackermans MT, 
Nederveen AJ, la Fleur SE, Romijn JA, Nieuwdorp M, Zhang 

Molecular mechanisms ofÂ hepatic lipid accumulation inÂ non-alcoholic fatty liver disease 3325
1 3
D, Samuel VT, Vatner DF, Petersen KF, Shulman GI, Serlie MJ 
(2017) Hepatic diacylglycerol-associated protein kinase cepsilon 
translocation links hepatic steatosis to hepatic insulin resistance 
in humans. Cell Rep 19:1997â€“2004. https://doi.org/10.1016/j.
celrep.2017.05.035
73. Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA, Chu 
X, Still CD, Gerhard GS, Han X, Dziura J, Petersen KF, Samuel 
VT, Shulman GI (2011) Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci USA 
108:16381â€“16385. https://doi.org/10.1073/pnas.1113359108
74. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, 
Cheung O, Sargeant C, Contos MJ, Sanyal AJ (2007) A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 
46:1081â€“1090. https://doi.org/10.1002/hep.21763
75. Fujita K, Nozaki Y, Wada K, Yoneda M, Fujimoto Y, Fujitake 
M, Endo H, Takahashi H, Inamori M, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nakajima A (2009) Dysfunctional 
very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology 
50:772â€“780. https://doi.org/10.1002/hep.23094
76. Walenbergh SM, Shiri-Sverdlov R (2015) Cholesterol is 
a significant risk factor for non-alcoholic steatohepatitis. 
Expert Rev Gastroenterol Hepatol 9:1343â€“1346. https://doi.
org/10.1586/17474124.2015.1092382
77. Reddy JK, Hashimoto T (2001) Peroxisomal beta-oxidation 
and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr 21:193â€“230. https://doi.
org/10.1146/annurev.nutr.21.1.193
78. Rao MS, Reddy JK (2001) Peroxisomal beta-oxidation and 
steatohepatitis. Semin Liver Dis 21:43â€“55. https://doi.
org/10.1055/s-2001-12928
79. Reddy JK, Rao MS (2006) Lipid metabolism and liver infammation. II. Fatty liver disease and fatty acid oxidation. Am J 
Physiol Gastrointest Liver Physiol 290:G852â€“G858. https://
doi.org/10.1152/ajpgi.00521.2005
80. Nassir F, Ibdah JA (2014) Role of mitochondria in nonalcoholic fatty liver disease. Int J Mol Sci 15:8713â€“8742. https://
doi.org/10.3390/ijms15058713
81. Kersten S, Stienstra R (2017) The role and regulation of the 
peroxisome proliferator activated receptor alpha in human 
liver. Biochimie 136:75â€“84. https://doi.org/10.1016/j.bioch
i.2016.12.019
82. Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B (2013) 
Mitochondrial adaptations and dysfunctions in nonalcoholic fatty 
liver disease. Hepatology 58:1497â€“1507. https://doi.org/10.1002/
hep.26226
83. Koek GH, Liedorp PR, Bast A (2011) The role of oxidative stress 
in non-alcoholic steatohepatitis. Clin Chim Acta 412:1297â€“1305. 
https://doi.org/10.1016/j.cca.2011.04.013
84. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FJ (1995) Targeted 
disruption of the alpha isoform of the peroxisome proliferatoractivated receptor gene in mice results in abolishment of the 
pleiotropic efects of peroxisome proliferators. Mol Cell Biol 
15:3012â€“3022. https://doi.org/10.1128/MCB.15.6.3012
85. Gao Q, Jia Y, Yang G, Zhang X, Boddu PC, Petersen B, Narsingam S, Zhu YJ, Thimmapaya B, Kanwar YS, Reddy JK (2015) 
PPARalpha-defcient ob/ob obese mice become more obese and 
manifest severe hepatic steatosis due to decreased fatty acid oxidation. Am J Pathol 185:1396â€“1408. https://doi.org/10.1016/j.
ajpath.2015.01.018
86. Francque S, Verrijken A, Caron S, Prawitt J, Paumelle R, 
Derudas B, Lefebvre P, Taskinen MR, Van Hul W, Mertens I, 
Hubens G, Van Marck E, Michielsen P, Van Gaal L, Staels B 
(2015) PPARalpha gene expression correlates with severity and 
histological treatment response in patients with non-alcoholic 
steatohepatitis. J Hepatol 63:164â€“173. https://doi.org/10.1016/j.
jhep.2015.02.019
87. Videla LA, Pettinelli P (2012) Misregulation of PPAR functioning and its pathogenic consequences associated with 
nonalcoholic fatty liver disease in human obesity. PPAR Res 
2012:107434. https://doi.org/10.1155/2012/107434
88. Dasarathy S, Kasumov T, Edmison JM, Gruca LL, Bennett C, 
Duenas C, Marczewski S, McCullough AJ, Hanson RW, Kalhan 
SC (2009) Glycine and urea kinetics in nonalcoholic steatohepatitis in human: efect of intralipid infusion. Am J Physiol Gastrointest Liver Physiol 297:G567â€“G575. https://doi.org/10.1152/
ajpgi.00042.2009
89. Dasarathy S, Yang Y, McCullough AJ, Marczewski S, Bennett 
C, Kalhan SC (2011) Elevated hepatic fatty acid oxidation, high 
plasma fbroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol 23:382â€“
388. https://doi.org/10.1097/MEG.0b013e328345c8c7
90. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos 
MJ, Sterling RK, Luketic VA, Shifman ML, Clore JN (2001) 
Nonalcoholic steatohepatitis: association of insulin resistance 
and mitochondrial abnormalities. Gastroenterology 120:1183â€“
1192. https://doi.org/10.1053/gast.2001.23256
91. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, 
Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M (2005) 
Insulin resistance in non-diabetic patients with non-alcoholic 
fatty liver disease: sites and mechanisms. Diabetologia 48:634â€“
642. https://doi.org/10.1007/s00125-005-1682-x
92. Miele L, Grieco A, Armuzzi A, Candelli M, Forgione A, Gasbarrini A, Gasbarrini G (2003) Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 
13C-octanoate breath test. Am J Gastroenterol 98:2335â€“2336. 
https://doi.org/10.1111/j.1572-0241.2003.07725.x
93. Kotronen A, Seppala-Lindroos A, Vehkavaara S, Bergholm R, 
Frayn KN, Fielding BA, Yki-Jarvinen H (2009) Liver fat and 
lipid oxidation in humans. Liver Int 29:1439â€“1446. https://doi.
org/10.1111/j.1478-3231.2009.02076.x
94. Croci I, Byrne NM, Choquette S, Hills AP, Chachay VS, Clouston AD, Oâ€™Moore-Sullivan TM, Macdonald GA, Prins JB, Hickman IJ (2013) Whole-body substrate metabolism is associated 
with disease severity in patients with non-alcoholic fatty liver 
disease. Gut 62:1625â€“1633. https://doi.org/10.1136/gutjnl-2012-
302789
95. Morris EM, Jackman MR, Johnson GC, Liu TW, Lopez JL, Kearney ML, Fletcher JA, Meers GM, Koch LG, Britton SL, Rector 
RS, Ibdah JA, MacLean PS, Thyfault JP (2014) Intrinsic aerobic 
capacity impacts susceptibility to acute high-fat diet-induced 
hepatic steatosis. Am J Physiol Endocrinol Metab 307:E355â€“
E364. https://doi.org/10.1152/ajpendo.00093.2014
96. von Loefelholz C, Docke S, Lock JF, Lieske S, Horn P, Kriebel J, Wahl S, Singmann P, de Las Heras Gala T, Grallert H, 
Raschzok N, Sauer IM, Heller R, Jahreis G, Claus RA, Bauer 
M, Stockmann M, Birkenfeld AL, Pfeifer AFH (2017) Increased 
lipogenesis in spite of upregulated hepatic 5â€²AMP-activated 
protein kinase in human non-alcoholic fatty liver. Hepatol Res 
47:890â€“901. https://doi.org/10.1111/hepr.12825
97. Perez-Carreras M, Del Hoyo P, Martin MA, Rubio JC, Martin 
A, Castellano G, Colina F, Arenas J, Solis-Herruzo JA (2003) 
Defective hepatic mitochondrial respiratory chain in patients 
with nonalcoholic steatohepatitis. Hepatology 38:999â€“1007. 
https://doi.org/10.1053/jhep.2003.50398
98. Koliaki C, Szendroedi J, Kaul K, Jelenik T, Nowotny P, Jankowiak F, Herder C, Carstensen M, Krausch M, Knoefel WT, Schlensak M, Roden M (2015) Adaptation of hepatic mitochondrial 
function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab 21:739â€“746. https://doi.org/10.1016/j.
cmet.2015.04.004

3326 D.Â H.Â Ipsen et al.
1 3
99. Rector RS, Thyfault JP, Uptergrove GM, Morris EM, Naples 
SP, Borengasser SJ, Mikus CR, Laye MJ, Laughlin MH, Booth 
FW, Ibdah JA (2010) Mitochondrial dysfunction precedes 
insulin resistance and hepatic steatosis and contributes to the 
natural history of non-alcoholic fatty liver disease in an obese 
rodent model. J Hepatol 52:727â€“736. https://doi.org/10.1016/j.
jhep.2009.11.030
100. Ahishali E, Demir K, Ahishali B, Akyuz F, Pinarbasi B, 
Poturoglu S, Ibrisim D, Gulluoglu M, Ozdil S, Besisik F, Kaymakoglu S, Boztas G, Cakaloglu Y, Mungan Z, Canberk Y, 
Okten A (2010) Electron microscopic fndings in non-alcoholic 
fatty liver disease: is there a diference between hepatosteatosis 
and steatohepatitis? J Gastroenterol Hepatol 25:619â€“626. https
://doi.org/10.1111/j.1440-1746.2009.06142.x
101. Ibdah JA, Perlegas P, Zhao Y, Angdisen J, Borgerink H, 
Shadoan MK, Wagner JD, Matern D, Rinaldo P, Cline JM 
(2005) Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. 
Gastroenterology 128:1381â€“1390. https://doi.org/10.1053/j.
gastro.2005.02.001
102. Rector RS, Morris EM, Ridenhour S, Meers GM, Hsu FF, Turk J, 
Ibdah JA (2013) Selective hepatic insulin resistance in a murine 
model heterozygous for a mitochondrial trifunctional protein 
defect. Hepatology 57:2213â€“2223. https://doi.org/10.1002/
hep.26285
103. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle 
C (1998) Hepatic cytochrome P450 2E1 is increased in patients 
with nonalcoholic steatohepatitis. Hepatology 27:128â€“133. https
://doi.org/10.1002/hep.510270121
104. Orellana M, Rodrigo R, Varela N, Araya J, Poniachik J, Csendes 
A, Smok G, Videla LA (2006) Relationship between inÂ vivo 
chlorzoxazone hydroxylation, hepatic cytochrome P450 2E1 
content and liver injury in obese non-alcoholic fatty liver disease 
patients. Hepatol Res 34:57â€“63. https://doi.org/10.1016/j.hepre
s.2005.10.001
105. Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall 
SD, Crabb DW (2003) Hepatic cytochrome P450 2E1 activity in 
nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 37:544â€“550. https://doi.org/10.1053/jhep.2003.50095
106. Chtioui H, Semela D, Ledermann M, Zimmermann A, Dufour 
JF (2007) Expression and activity of the cytochrome P450 2E1 
in patients with nonalcoholic steatosis and steatohepatitis. Liver 
Int 27:764â€“771. https://doi.org/10.1111/j.1478-3231.2007.01524
.x
107. Nakamuta M, Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Yada M, Yada R, Takemoto R, Fukuizumi K, Harada N, 
Taketomi A, Maehara Y, Nakashima M, Enjoji M (2008) The signifcance of diferences in fatty acid metabolism between obese 
and non-obese patients with non-alcoholic fatty liver disease. Int 
J Mol Med 22:663â€“667. https://doi.org/10.3892/ijmm_00000070
108. Dirkx R, Vanhorebeek I, Martens K, Schad A, Grabenbauer 
M, Fahimi D, Declercq P, Van Veldhoven PP, Baes M (2005) 
Absence of peroxisomes in mouse hepatocytes causes mitochondrial and ER abnormalities. Hepatology 41:868â€“878. https://doi.
org/10.1002/hep.20628
109. Fan CY, Pan J, Usuda N, Yeldandi AV, Rao MS, Reddy JK (1998) 
Steatohepatitis, spontaneous peroxisome proliferation and liver 
tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. 
Implications for peroxisome proliferator-activated receptor alpha 
natural ligand metabolism. J Biol Chem 273:15639â€“15645
110. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson 
BW, Klein S (2008) Alterations in adipose tissue and hepatic 
lipid kinetics in obese men and women with nonalcoholic 
fatty liver disease. Gastroenterology 134:424â€“431. https://doi.
org/10.1053/j.gastro.2007.11.038
111. Kawano Y, Cohen DE (2013) Mechanisms of hepatic triglyceride 
accumulation in non-alcoholic fatty liver disease. J Gastroenterol 
48:434â€“441. https://doi.org/10.1007/s00535-013-0758-5
112. Tanoli T, Yue P, Yablonskiy D, Schonfeld G (2004) Fatty liver 
in familial hypobetalipoproteinemia: roles of the APOB defects, 
intra-abdominal adipose tissue, and insulin sensitivity. J Lipid 
Res 45:941â€“947. https://doi.org/10.1194/jlr.M300508-JLR200
113. Berriot-Varoqueaux N, Aggerbeck LP, Samson-Bouma M, Wetterau JR (2000) The role of the microsomal triglygeride transfer 
protein in abetalipoproteinemia. Annu Rev Nutr 20:663â€“697. 
https://doi.org/10.1146/annurev.nutr.20.1.663
114. Zhang XQ, Xu CF, Yu CH, Chen WX, Li YM (2014) Role of 
endoplasmic reticulum stress in the pathogenesis of nonalcoholic 
fatty liver disease. World J Gastroenterol 20:1768â€“1776. https://
doi.org/10.3748/wjg.v20.i7.1768
115. Ota T, Gayet C, Ginsberg HN (2008) Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Investig 118:316â€“332. https://doi.
org/10.1172/JCI32752
116. Ameen C, Edvardsson U, Ljungberg A, Asp L, Akerblad P, 
Tuneld A, Olofsson SO, Linden D, Oscarsson J (2005) Activation of peroxisome proliferator-activated receptor alpha increases 
the expression and activity of microsomal triglyceride transfer 
protein in the liver. J Biol Chem 280:1224â€“1229. https://doi.
org/10.1074/jbc.M412107200
117. Pawlak M, Lefebvre P, Staels B (2015) Molecular mechanism of 
PPARalpha action and its impact on lipid metabolism, infammation and fbrosis in non-alcoholic fatty liver disease. J Hepatol 
62:720â€“733. https://doi.org/10.1016/j.jhep.2014.10.039
118. Tessari P, Coracina A, Cosma A, Tiengo A (2009) Hepatic lipid 
metabolism and non-alcoholic fatty liver disease. Nutr Metab 
Cardiovasc Dis 19:291â€“302. https://doi.org/10.1016/j.numec
d.2008.12.015
119. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen 
A, Westerbacka J, Vehkavaara S, Hakkinen A, Olofsson SO, YkiJarvinen H, Boren J (2006) Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 
49:755â€“765. https://doi.org/10.1007/s00125-005-0125-z
120. Horton JD, Shimano H, Hamilton RL, Brown MS, Goldstein JL 
(1999) Disruption of LDL receptor gene in transgenic SREBP1a mice unmasks hyperlipidemia resulting from production of 
lipid-rich VLDL. J Clin Investig 103:1067â€“1076. https://doi.
org/10.1172/JCI6246
121. Nakamuta M, Fujino T, Yada R, Yada M, Yasutake K, Yoshimoto T, Harada N, Higuchi N, Kato M, Kohjima M, Taketomi A, 
Maehara Y, Nakashima M, Kotoh K, Enjoji M (2009) Impact of 
cholesterol metabolism and the LXRalpha-SREBP-1c pathway 
on nonalcoholic fatty liver disease. Int J Mol Med 23:603â€“608. 
https://doi.org/10.3892/ijmm_00000170
122. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair 
KS (2002) Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 35:898â€“904. https://doi.org/10.1053/
jhep.2002.32527
123. Shindo N, Fujisawa T, Sugimoto K, Nojima K, Oze-Fukai A, 
Yoshikawa Y, Wang X, Yasuda O, Ikegami H, Rakugi H (2010) 
Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model. J 
Hepatol 52:903â€“912. https://doi.org/10.1016/j.jhep.2009.12.033
124. Nagaya T, Tanaka N, Suzuki T, Sano K, Horiuchi A, Komatsu 
M, Nakajima T, Nishizawa T, Joshita S, Umemura T, Ichijo T, 
Matsumoto A, Yoshizawa K, Nakayama J, Tanaka E, Aoyama 
T (2010) Down-regulation of SREBP-1c is associated with the 
development of burned-out NASH. J Hepatol 53:724â€“731. https
://doi.org/10.1016/j.jhep.2010.04.033
125. Santhekadur PK, Kumar DP, Sanyal AJ (2018) Preclinical models of non-alcoholic fatty liver disease. J Hepatol 68:230â€“237

Molecular mechanisms ofÂ hepatic lipid accumulation inÂ non-alcoholic fatty liver disease 3327
1 3
126. Van Herck MA, Vonghia L, Francque SM (2017) Animal models 
of nonalcoholic fatty liver diseaseâ€”a starterâ€™s guide. Nutrients 
9:1072
127. Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, 
Yokoyama M, Honda M, Zen Y, Nakanuma Y, Miyamoto K, 
Kaneko S (2007) Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 46:1392â€“
1403. https://doi.org/10.1002/hep.21874
128. Schattenberg JM, Galle PR (2010) Animal models of non-alcoholic steatohepatitis: of mice and man. Dig Dis 28:247â€“254. 
https://doi.org/10.1159/000282097
129. Sanches SC, Ramalho LN, Augusto MJ, da Silva DM, Ramalho 
FS (2015) Nonalcoholic steatohepatitis: a search for factual 
animal models. Biomed Res Int 2015:574832. https://doi.
org/10.1155/2015/574832
130. Asgharpour A, Cazanave SC, Pacana T, Seneshaw M, Vincent R, 
Banini BA, Kumar DP, Daita K, Min HK, Mirshahi F, Bedossa 
P, Sun X, Hoshida Y, Koduru SV, Contaifer D Jr, Warncke UO, 
Wijesinghe DS, Sanyal AJ (2016) A diet-induced animal model 
of non-alcoholic fatty liver disease and hepatocellular cancer. J 
Hepatol 65:579â€“588
131. Tveden-Nyborg P, Birck MM, Ipsen DH, Thiessen T, Feldmann 
LB, Lindblad MM, Jensen HE, Lykkesfeldt J (2016) Dietinduced dyslipidemia leads to nonalcoholic fatty liver disease 
and oxidative stress in guinea pigs. Transl Res 168:146â€“160. 
https://doi.org/10.1016/j.trsl.2015.10.001
132. Ipsen DH, Tveden-Nyborg P, Rolin B, Rakipovski G, Beck M, 
Mortensen LW, Faerk L, Heegaard PM, Moller P, Lykkesfeldt 
J (2016) High-fat but not sucrose intake is essential for induction of dyslipidemia and non-alcoholic steatohepatitis in guinea 
pigs. Nutr Metab (Lond) 13:51. https://doi.org/10.1186/s1298
6-016-0110-1
133. Ye P, Cheah IK, Halliwell B (2013) A high-fat and cholesterol diet causes fatty liver in guinea pigs. The role of iron and 
oxidative damage. Free Radic Res 47:602â€“613. https://doi.
org/10.3109/10715762.2013.806796
134. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, 
Wands JR, Fava JL, Wing RR (2010) Randomized controlled 
trial testing the efects of weight loss on nonalcoholic steatohepatitis. Hepatology 51:121â€“129. https://doi.org/10.1002/hep.23276
135. Middleton KR, Anton SD, Perri MG (2013) Long-term adherence to health behavior change. Am J Lifestyle Med 7:395â€“404
136. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl 
AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, 
Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR, Nash CRN (2010) Pioglitazone, vitamin 
E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 
362:1675â€“1685. https://doi.org/10.1056/NEJMoa0907929
137. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van 
Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl 
AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark 
JM, Tonascia J, Brunt EM, Kleiner DE, Doo E (2015) Farnesoid 
X nuclear receptor ligand obeticholic acid for non-cirrhotic, nonalcoholic steatohepatitis (FLINT): a multicentre, randomised, 
placebo-controlled trial. Lancet 385:956â€“965
138. Friedman SL, Ratziu V, Harrison SA, Abdelmalek MF, Aithal 
GP, Caballeria J, Francque S, Farrell G, Kowdley KV, Craxi A, 
Simon K, Fischer L, Melchor-Khan L, Vest J, Wiens BL, Vig P, 
Seyedkazemi S, Goodman Z, Wong VW, Loomba R, Tacke F, 
Sanyal A, Lefebvre E (2018) A randomized, placebo-controlled 
trial of cenicriviroc for treatment of nonalcoholic steatohepatitis 
with fbrosis. Hepatology 67:1754â€“1767. https://doi.org/10.1002/
hep.29477
139. Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, 
Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP, Subramanian GM, McHutchison JG, Goodman ZD, Afdhal NH, Charlton 
MR (2017) The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology. https://doi.org/10.1002/hep.29514
140. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, 
Hazlehurst JM, Guo K, Abouda G, Aldersley MA, Stocken D, 
Gough SC, Tomlinson JW, Brown RM, Hubscher SG, Newsome 
PN (2016) Liraglutide safety and efcacy in patients with nonalcoholic steatohepatitis (LEAN): a multicentre, double-blind, 
randomised, placebo-controlled phase 2 study. Lancet 387:679â€“
690. https://doi.org/10.1016/s0140-6736(15)00803-x
141. Konerman MA, Jones JC, Harrison SA (2018) Pharmacotherapy 
for NASH: current and emerging. J Hepatol 68:362â€“375. https://
doi.org/10.1016/j.jhep.2017.10.015

